Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population

Kim E Innes12*, Jeffrey H Wimsatt3, Stephanie Frisbee4 and Alan M Ducatman56

Author Affiliations

1 Department of Epidemiology, West Virginia University School of Public Health, PO Box 9190, Morgantown, WV 26506-9190, USA

2 University of Virginia Health System, Charlottesville, Virginia 22908-0782, USA

3 Department of Medicine, West Virginia University School of Medicine, Morgantown, WV 26506-9190, USA

4 Department of Health Policy, Management and Leadership, West Virginia University School of Public Health, PO Box 9190, Morgantown, WV 26506-9190, USA

5 Department of Environmental and Occupational Health, West Virginia University School of Public Health, Morgantown, WV 26506-9190, USA

6 Department of Medicine and Cancer Center, West Virginia University School of Medicine, Morgantown, WV 26506-9190, USA

For all author emails, please log on.

BMC Cancer 2014, 14:45  doi:10.1186/1471-2407-14-45

Published: 27 January 2014

Abstract

Background

Perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) are persistent environmental contaminants that affect metabolic regulation, inflammation, and other factors implicated in the development and progression of colorectal cancer (CRC). However, the link between these compounds and CRC remains unknown. In this cross-sectional study, we investigated the association of CRC diagnosis to PFOA and PFOS blood levels in a large Appalachian population.

Methods

Participants were 47,359 adults ≥ 21 years of age and residing in six PFOA-contaminated water districts in the mid-Ohio Valley (N = 47,151 cancer-free adults, 208 cases of primary CRC). All participants completed a comprehensive health survey between 2005 and 2006; serum levels of PFOA, PFOS, and a range of other blood markers were also measured. Medical history was assessed via self report and cancer diagnosis confirmed via chart review.

Results

CRC showed a strong inverse, dose–response association with PFOS serum levels (odds ratio (OR) adjusted for potential confounders = 0.2, 95% confidence interval (CI) 0.2,0.3) for highest vs. lowest quartile of PFOS, P-trend < 0.00001) and a significant, but more modest inverse association with PFOA (adjusted OR = 0.6 (CI 0.4, 0.9) for highest vs. lowest quartile, P-trend = 0.001). These inverse associations were stronger in those diagnosed within the previous 6 years and resident in the same water district for a minimum of 10–15 years preceding assessment. The relationship between PFOA and CRC was also more pronounced in men and leaner adults, and showed a stronger linear trend at lower exposure levels.

Conclusions

In this large cross-sectional study, we found a strong, inverse association between PFOS and likelihood of CRC diagnosis and a significant, although more modest inverse association between PFOA and CRC. If confirmed in prospective investigations, these findings may aid in identifying new strategies for CRC prevention and treatment and inform future studies regarding mechanisms underlying CRC pathogenesis.

Keywords:
Colorectal cancer epidemiology; Colon cancer; Perfluorooctanoate (PFOA); Perfluorooctane sulfonate (PFOS); Perfluorocarbons; Perfluoroalkyl acids; Peroxisome proliferator-activated receptors (PPARs); Gender; Body mass index; Inflammation